Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Pediatrics
Published in: BMC Pediatrics 1/2021

Open Access 01-12-2021 | Patent Ductus Arteriosus | Research article

Retrospective comparison of death or neurodevelopmental outcomes in extremely low birth weight preterm infants following different management options of haemodynamically significant patent ductus arteriosus

Authors: Jania Jia-Ying Wu, Krishnamoorthy Niduvaje, Le ye Lee, Zubair Amin

Published in: BMC Pediatrics | Issue 1/2021

Login to get access

Abstract

Background

Optimal management of haemodynamically significant patent ductus arteriosus (HsPDA) in premature babies remains controversial. Our aim is to compare death and/or adverse neurodevelopmental outcomes in extremely low birth weight (ELBW) infants with HsPDA who were managed with conservative [C], medical [M] and/or surgical [S] treatment, with secondary aim to examine short-term morbidities among [S] and [C] groups. The study also compared outcomes in very low birth weight (VLBW) infants with HsPDA and non-HsPDA.

Methods

A retrospective study of VLBW preterm infants born before 29 weeks in Singapore from 2007 to 2016 was conducted.

Results

A total of 474 VLBW infants were admitted in NUH from 2007 to 2016. Infants aged between 24 + 0 and 28 + 6 weeks of gestation, weighing ≤1500 g and diagnosed with patent ductus arteriosus (PDA) were included in the study, of which 172 infants (124 HsPDA and 48 non-HsPDA) were analyzed. Among infants with HsPDA, 17 infants were managed with [C], 83 with [M] and 24 with [S]. Mortality was not increased regardless of the presence of HsPDA or treatment received. Infants with non-HsPDA were less likely to have isolated speech delay (p < 0.05), but not global developmental delay (GDD). No significant differences in neurodevelopmental outcomes such as hearing loss, cerebral palsy (CP) and speech delay were found. [M + S] infants were at a higher risk of developing chronic lung disease (CLD) (OR 6.83, p < 0.05) and short-term growth failure compared to [C] infants. They were significantly shorter and had a smaller head circumference at discharge (p < 0.05). [M + S] infants also had elevated creatinine compared to those in group [C] (81.1 ± 24.1 vs 48.3 ± 11.8 umol/L, p < 0.000).

Conclusions

Compared to conservative management, infants requiring [M + S] treatment for HsPDA were more likely to have short-term complications such as CLD, elevated creatinine, and poorer growth. Despite a more turbulent postnatal course, death and/or adverse neurodevelopmental outcomes were not worse in infants managed with [M + S].
Literature
1.
Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med. 2000;343(10):728–30.CrossRef
2.
3.
4.
Arlettaz R. Echocardiographic evaluation of patent Ductus Arteriosus in preterm infants. Front Pediatr. 2017;5:147.CrossRef
5.
Engeseth MS, Engan M, Clemm H, Vollsæter M, Nilsen RM, Markestad T, et al. Voice and exercise related respiratory symptoms in extremely preterm born children after neonatal patent Ductus Arteriosus. Front Pediatr. 2020;8:150.CrossRef
6.
7.
Shepherd JL, Noori S. What is a hemodynamically significant PDA in preterm infants? Congenit Heart Dis. 2019;14(1):21–6.PubMed
8.
Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol. 2010;30(4):241–52.CrossRef
9.
Ibrahim TK, Haium AA, Chandran S, Rajadurai VS. Current controversies in the management of patent ductus arteriosus in preterm infants. Indian Pediatr. 2014;51(4):289–94.CrossRef
10.
Gillam-Krakauer M, Reese J. Diagnosis and Management of Patent Ductus Arteriosus. Neoreviews. 2018;19(7):e394–402.CrossRef
11.
Sekar KC, Corff KE. Treatment of patent ductus arteriosus: indomethacin or ibuprofen? J Perinatol. 2008;28(Suppl 1):S60–2.CrossRef
12.
Teixeira LS, Shivananda SP, Stephens D, Van Arsdell G, McNamara PJ. Postoperative cardiorespiratory instability following ligation of the preterm ductus arteriosus is related to early need for intervention. J Perinatol. 2008;28(12):803–10.CrossRef
13.
Engeseth MS, Olsen NR, Maeland S, Halvorsen T, Goode A, Røksund OD. Left vocal cord paralysis after patent ductus arteriosus ligation: a systematic review. Paediatr Respir Rev. 2018;27:74–85.PubMed
14.
Noori S. Patent ductus arteriosus in the preterm infant: to treat or not to treat? J Perinatol. 2010;30(Suppl):S31–7.CrossRef
15.
Mitra S, Disher T. Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants. Cochrane Database Syst Rev. 2019;2019(2):CD013278.PubMedCentral
16.
Bhola K, Foster JP, Osborn DA. Chest shielding for prevention of a haemodynamically significant patent ductus arteriosus in preterm infants receiving phototherapy. Cochrane Database Syst Rev. 2015;(11):Cd009816.
17.
Fenton TR. A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format. BMC Pediatr. 2003;3:13.CrossRef
18.
Ezz-Eldin ZM, Hamid TA, Youssef MR, Nabil Hel D. Clinical risk index for babies (CRIB II) scoring system in prediction of mortality in premature babies. J Clin Diagn Res. 2015;9(6):Sc08–11.PubMedPubMedCentral
19.
Dabis JM, Abman SH. Bronchopulmonary dysplasia. In: Spitzer AR, editor. Intensive Care of the Fetus and Neonate. 2nd ed: Mosby; 2005. p. 729–49.
20.
Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92(4):529–34.CrossRef
21.
Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187(1):1–7.CrossRef
22.
Good WV. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233–48 discussion 248-250.PubMedPubMedCentral
23.
Jobe AH. The new bronchopulmonary dysplasia. Curr Opin Pediatr. 2011;23(2):167–72.CrossRef
24.
25.
Isayama T, Mirea L, Mori R, Kusuda S, Fujimura M, Lee SK, et al. Patent ductus arteriosus management and outcomes in Japan and Canada: comparison of proactive and selective approaches. Am J Perinatol. 2015;32(11):1087–94.CrossRef
26.
Mydam J, Rastogi A, Naheed ZJ. Base excess and hematocrit predict response to indomethacin in very low birth weight infants with patent ductus arteriosus. Ital J Pediatr. 2019;45(1):107.CrossRef
27.
Valerio E, Valente MR, Salvadori S, Frigo AC, Baraldi E, Lago P. Intravenous paracetamol for PDA closure in the preterm: a single-center experience. Eur J Pediatr. 2016;175(7):953–66.CrossRef
28.
Hermansen CL, Mahajan A. Newborn respiratory distress. Am Fam Physician. 2015;92(11):994–1002.PubMed
29.
To S, Lee M, Siu KL. Predictors of failure of medical closure of patent ductus arteriosus in preterm infants. In: 13th congress of the Asian Society for Pediatric Research: 2017. Hong Kong: Hong Kong S.A.R; 2017.
30.
Chorne N, Leonard C, Piecuch R, Clyman RI. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics. 2007;119(6):1165–74.CrossRef
31.
Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in Preterms. J Pediatr. 2007;150(3):229–34 234.e221.CrossRef
32.
Madan JC, Kendrick D, Hagadorn JI, Frantz ID 3rd. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics. 2009;123(2):674–81.CrossRef
33.
Janz-Robinson EM, Badawi N, Walker K, Bajuk B, Abdel-Latif ME. Neurodevelopmental outcomes of premature infants treated for patent Ductus Arteriosus: a population-based cohort study. J Pediatr. 2015;167(5):1025–1032.e1023.CrossRef
34.
Cotton RB, Stahlman MT, Bender HW, Graham TP, Catterton WZ, Kovar I. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. J Pediatr. 1978;93(4):647–51.CrossRef
35.
Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O'Shea TM. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina neonatologists association. Pediatrics. 1999;104(6):1345–50.CrossRef
36.
Adrouche-Amrani L, Green RS, Gluck KM, Lin J. Failure of a repeat course of cyclooxygenase inhibitor to close a PDA is a risk factor for developing chronic lung disease in ELBW infants. BMC Pediatr. 2012;12:10.CrossRef
37.
Clyman RI, Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Håkansson S, et al. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent Ductus Arteriosus at 1 week of age. J Pediatr. 2019;205:41–48.e46.CrossRef
38.
Hundscheid T, Onland W, van Overmeire B, Dijk P, van Kaam A, Dijkman KP, et al. Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial). BMC Pediatr. 2018;18(1):262.CrossRef
39.
Tashiro J, Wang B, Sola JE, Hogan AR, Neville HL, Perez EA. Patent ductus arteriosus ligation in premature infants in the United States. J Surg Res. 2014;190(2):613–22.CrossRef
40.
Agarwal P, Sriram B, Rajadurai VS. Neonatal outcome of extremely preterm Asian infants ⩽28 weeks over a decade in the new millennium. J Perinatol. 2015;35(4):297–303.CrossRef
41.
Bohlin K, Gudmundsdottir T, Katz-Salamon M, Jonsson B, Blennow M. Implementation of surfactant treatment during continuous positive airway pressure. J Perinatol. 2007;27(7):422–7.CrossRef
42.
Mercer JS, Vohr BR, McGrath MM, Padbury JF, Wallach M, Oh W. Delayed cord clamping in very preterm infants reduces the incidence of intraventricular hemorrhage and late-onset sepsis: a randomized, controlled trial. Pediatrics. 2006;117(4):1235–42.CrossRef
43.
Rabe H, Diaz-Rossello JL, Duley L, Dowswell T. Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes. Cochrane Database Syst Rev. 2012;8:CD003248.
Metadata
Title
Retrospective comparison of death or neurodevelopmental outcomes in extremely low birth weight preterm infants following different management options of haemodynamically significant patent ductus arteriosus
Authors
Jania Jia-Ying Wu
Krishnamoorthy Niduvaje
Le ye Lee
Zubair Amin
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2021
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-021-02920-9

Other articles of this Issue 1/2021

BMC Pediatrics 1/2021 Go to the issue

Research

Developing practical clinical tools for predicting neonatal mortality at a neonatal intensive care unit in Tanzania

Correction

Correction to: Study protocol and rationale of the “Cogniaction project” a cross-sectional and randomized controlled trial about physical activity, brain health, cognition, and educational achievement in schoolchildren

Case report

Spinal arteriovenous malformation in a pediatric patient with a history of congenital syphilis: a case report

Research article

Regional variation in cost of neonatal intensive care for extremely preterm infants

Research

Rare novel LPL mutations are associated with neonatal onset lipoprotein lipase (LPL) deficiency in two cases

Research

Association between humidifier disinfectant exposure during infancy and subsequent neuropsychiatric outcomes during childhood: a nation-wide cross-sectional study